The majority of patients with recurrent glioblastoma remain alive following treatment with an experimental immune-modulating combination, according to a clinical trial update from Immunitybio.
News
Treatment with relacorilant plus standard chemotherapy was shown in a clinical trial to significantly improve survival compared with chemo alone for people with hard-to-treat ovarian…
A clinical trial in Australia that’s testing the genetic therapy KLN-1010 in people with hard-to-treat multiple myeloma has won regulatory approval to add new…
The U.S. Food and Drug Administration (FDA) has granted breakthrough designation to soficabtagene geleucel (sofi-cel), a cell therapy designed to treat relapsed or refractory T-cell…
After a year of treatment with the experimental medication atebimetinib as an add-on to chemotherapy, about two-thirds of pancreatic cancer patients in an ongoing…
Curasight‘s experimental cancer therapy, uTREAT, has successfully reached its target in the brain of the first patient dosed in a Phase 1 clinical trial.
The U.S. Food and Drug Administration (FDA) has granted its breakthrough therapy designation to sofetabart mipitecan as a potential treatment for people with platinum-resistant epithelial…
Treatment with Tecvayli (teclistamab) was better than standard therapies at delaying disease progression and prolonging survival among previously-treated myeloma patients in a Phase…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NP-G2-044, an experimental treatment for pancreatic cancer that’s currently in clinical…
Treatment with DeltEx DRI, a cell therapy developed by In8bio, is prolonging survival outcomes among people with newly diagnosed glioblastoma in a clinical…
